On Jul. 1, 2021, Moderna confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP) approval of the Recipharm Monts site on Jun. 11, 2021, drug product manufacture of the Moderna COVID-19 vaccine at the site in France had begun.

Moderna’s partnership with Recipharm is reflective of the Company’s commitment to expanding its global manufacturing capacity. Investments made earlier this year are expected to enable a doubling of drug substance manufacturing in Europe. When completed, the investments are expected to also result in an increase in safety stock of raw materials and finished product used to deliver committed volumes.

The European Commission granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, based upon the recommendation of the European Medicines Agency (EMA) for use of the COVID-19 Vaccine Moderna for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older.